Literature DB >> 16480701

Detection of Hunter syndrome (mucopolysaccharidosis type II) in Taiwanese: biochemical and linkage studies of the iduronate-2-sulfatase gene defects in MPS II patients and carriers.

Shuan-Pei Lin1, Jui-Hung Chang, Guey-Jen Lee-Chen, Dar-Shong Lin, Hsiang-Yu Lin, Chih-Kuang Chuang.   

Abstract

BACKGROUND: Hunter syndrome (mucopolysaccharidosis type II) is an X-linked recessive lysosomal storage disease caused by a defect of the iduronate-2-sulfatase (IDS) gene. The result is impaired IDS enzyme function.
METHODS: To characterize the biochemical and molecular defects in IDS-deficient patients and their families, we measured IDS enzyme activity by fluorimetric enzyme assay and identified the IDS gene mutations in 14 unrelated Taiwanese patients with varying clinical phenotypes. In addition, haplotype analysis was also performed.
RESULTS: Three novel (IVS2+1G>C, 1055del12, and G489D) and 7 previously reported (N63K, P228L, K347E, R468Q, R468W, I485R, and 1241delAG) mutations were found. Together R468Q and R468W account for 42.8% mutations found in our patients. Haplotype analysis using IDS flanking markers DXS1113 and DXS1123 revealed that the unrelated R468Q alleles were independent in origin whereas the unrelated R468W alleles are probably of the same origin. The R468Q mutation in patient 1150 and I485R mutation in patient 710 occurred de novo in male meioses. Once the mutation in a family was identified, restriction analysis was also performed for rapid diagnosis of female carriers in 8 families. Leukocyte IDS measurement revealed significantly wide range of IDS activity in normal controls and MPS II carriers (19.2 - 70.6 vs. 8.4 - 26.6 nmol/h/mg cell protein). The average leukocyte IDS activity of normal controls (n=43) was 43.9+/-13.3 nmol/h/mg protein, whereas patients with MPS II (n=14) had <5% of mean normal IDS activity (0.9+/-0.6 nmol/h/mg protein), and carriers (n=13) had a mean activity of 17.5 (+/-5.7) nmol/h/mg protein. The mean leukocyte IDS activity in female carriers was less than a half of the normal level.
CONCLUSION: Due to a small overlapping range of normal and carriers, the level of enzyme activity cannot be used alone for carrier detection.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16480701     DOI: 10.1016/j.cca.2006.01.001

Source DB:  PubMed          Journal:  Clin Chim Acta        ISSN: 0009-8981            Impact factor:   3.786


  12 in total

1.  Deep Genotyping of the IDS Gene in Colombian Patients with Hunter Syndrome.

Authors:  Johanna Galvis; Jannet González; Alfredo Uribe; Harvy Velasco
Journal:  JIMD Rep       Date:  2015-02-15

2.  Epidemiology of mucopolysaccharidoses.

Authors:  Shaukat A Khan; Hira Peracha; Diana Ballhausen; Alfred Wiesbauer; Marianne Rohrbach; Matthias Gautschi; Robert W Mason; Roberto Giugliani; Yasuyuki Suzuki; Kenji E Orii; Tadao Orii; Shunji Tomatsu
Journal:  Mol Genet Metab       Date:  2017-05-26       Impact factor: 4.797

3.  Demographic characteristics and distribution of lysosomal storage disorder subtypes in Eastern China.

Authors:  Xueru Chen; Wenjuan Qiu; Jun Ye; Lianshu Han; Xuefan Gu; Huiwen Zhang
Journal:  J Hum Genet       Date:  2016-01-07       Impact factor: 3.172

4.  Clinical and biochemical studies in mucopolysaccharidosis type II carriers.

Authors:  I V D Schwartz; L L C Pinto; G Breda; L Lima; M G Ribeiro; J G Mota; A X Acosta; P Correia; D D G Horovitz; C G G Porciuncula; E Lipinski-Figueiredo; A C Fett-Conte; R P Oliveira Sobrinho; D Y J Norato; A C Paula; C A Kim; A R Duarte; R Boy; S Leistner-Segal; M G Burin; R Giugliani
Journal:  J Inherit Metab Dis       Date:  2009-10-10       Impact factor: 4.982

5.  Diagnosing Hunter syndrome in pediatric practice: practical considerations and common pitfalls.

Authors:  Barbara K Burton; Roberto Giugliani
Journal:  Eur J Pediatr       Date:  2012-03-01       Impact factor: 3.183

6.  Analysis of the IDS gene in 38 patients with Hunter syndrome: the c.879G>A (p.Gln293Gln) synonymous variation in a female create exonic splicing.

Authors:  Huiwen Zhang; Jing Li; Xinshun Zhang; Yu Wang; Wenjuan Qiu; Jun Ye; Lianshu Han; Xiaolan Gao; Xuefan Gu
Journal:  PLoS One       Date:  2011-08-04       Impact factor: 3.240

7.  Molecular analysis of iduronate -2- sulfatase gene in Tunisian patients with mucopolysaccharidosis type II.

Authors:  Latifa Chkioua; Souhir Khedhiri; Salima Ferchichi; Rémy Tcheng; Henda Chahed; Roseline Froissart; Christine Vianey-Saban; Sandrine Laradi; Abdelhedi Miled
Journal:  Diagn Pathol       Date:  2011-05-23       Impact factor: 2.644

8.  Mucopolysaccharidoses in northern Brazil: Targeted mutation screening and urinary glycosaminoglycan excretion in patients undergoing enzyme replacement therapy.

Authors:  Gustavo M Viana; Nathália O de Lima; Rosely Cavaleiro; Erik Alves; Isabel C N Souza; Raimunda Feio; Sandra Leistner-Segal; Ida Schwartz; Roberto Giugliani; Luiz C Santana da Silva
Journal:  Genet Mol Biol       Date:  2011-07-01       Impact factor: 1.771

9.  Clinical, biochemical and molecular characteristics of Filipino patients with mucopolysaccharidosis type II - Hunter syndrome.

Authors:  Mary Anne D Chiong; Daffodil M Canson; Mary Ann R Abacan; Melissa Mae P Baluyot; Cynthia P Cordero; Catherine Lynn T Silao
Journal:  Orphanet J Rare Dis       Date:  2017-01-11       Impact factor: 4.123

10.  Causes of death and clinical characteristics of 34 patients with Mucopolysaccharidosis II in Taiwan from 1995-2012.

Authors:  Hsiang-Yu Lin; Chih-Kuang Chuang; Yu-Hsiu Huang; Ru-Yi Tu; Fang-Ju Lin; Shio Jean Lin; Pao Chin Chiu; Dau-Ming Niu; Fuu-Jen Tsai; Wuh-Liang Hwu; Yin-Hsiu Chien; Ju-Li Lin; Yen-Yin Chou; Wen-Hui Tsai; Tung-Ming Chang; Shuan-Pei Lin
Journal:  Orphanet J Rare Dis       Date:  2016-06-27       Impact factor: 4.123

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.